GLYC
Glycomimetics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Buy"
EPS Beats Expectation
Revenue Keeps Dropping
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GLYC
Glycomimetics, Inc.
A late clinical-stage biotechnology company that developing glycobiology-based therapies for cancers and inflammatory diseases
Biological Technology
Invalid Date
01/10/2014
NASDAQ Stock Exchange
4
12-31
Common stock
9708 Medical Center Drive
, Rockville
, Maryland 20850
--
Founded in Delaware in 2003, Glycomimetics, Inc., is a late-stage clinical biotechnology company dedicated to improving the lives of patients with cancer and inflammatory diseases by inhibiting carbohydrate interactions that occur on the cell surface. The company is developing a proprietary pipeline of sugar mimics, small molecules that mimic the structure of carbohydrates and are involved in important biological processes that inhibit carbohydrate disease-related functions.
Company Financials
EPS
GLYC has released its 2024 Q1 earnings. EPS was reported at -0.17, versus the expected -0.16, missing expectations. The chart below visualizes how GLYC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available